29.69
29.69 (0%)
As of Apr 17, 2025
Janux Therapeutics, Inc. [JANX]
Source:
Company Overview
Janux Therapeutics, Inc is an innovative clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Our proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr).
| Country | United States |
| Headquarters | san diego, california |
| Phone Number | (858) 751-4493 |
| Industry | manufacturing |
| CEO | David Campbell |
| Website | www.clinicaltrials.gov |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $10.6 |
| Operating Profit | $-98.8 |
| Net Income | $-69 |
| Net Cash | $411.4 |
Profit Ratios
| Gross Margin | $10.6 |
| Operating Margin | -933.6 |
| Profit as % of Revenues | -15.4% |
| Profit as % of Assets | -9.6% |
| Profit as % of Stockholder Equity | -6.8% |
Management Effectiveness
| Return on Equity | -6.8% |
| Return on Assets | -6.5% |
| Turnover Ratio | 1.5% |
| EBITA | $-98.8 |
Balance Sheet and Cash Flow Measures
| Total Assets | $1,061.5 |
| Total Liabilities | $38.7 |
| Operating Cash Flow | $-43.8 |
| Investing Cash Flow | $-258 |
| Financing Cash Flow | $713.2 |
